Skip to main content
Premium Trial:

Request an Annual Quote

NeoGenomics Moves to Nasdaq Capital Market

NEW YORK (GenomeWeb News) – NeoGenomics has been approved to list its shares on the Nasdaq Capital Market, the Ft. Myers, Fla.-based firm said today.

The company's stock is currently traded on the OTC Bulletin Board under ticker symbol "NGNM." Starting Dec. 10, NeoGenomics will list on Nasdaq under ticker symbol "NEO."

"The transition to the Nasdaq Capital Market is a significant milestone for NeoGenomics and reflects the strong revenue and operating income growth we have achieved over the last several years," NeoGenomics Chairman and CEO Douglas VanOort said in a statement. "We believe this move will increase the visibility and liquidity of our shares in the market."

In late October NeoGenomics reported that its revenues in the third quarter improved 26 percent year over year.

In late afternoon trading today, shares of the company rose 4 percent to $2.81

The Scan

Harvard Team Report One-Time Base Editing Treatment for Motor Neuron Disease in Mice

A base-editing approach restored SMN levels and improved motor function in a mouse model of spinal muscular atrophy, a new Science paper reports.

International Team Examines History of North American Horses

Genetic and other analyses presented in Science find that horses spread to the northern Rockies and Great Plains by the first half of the 17th century.

New Study Examines Genetic Dominance Within UK Biobank

Researchers analyze instances of genetic dominance within UK Biobank data, as they report in Science.

Cell Signaling Pathway Identified as Metastasis Suppressor

A new study in Nature homes in on the STING pathway as a suppressor of metastasis in a mouse model of lung cancer.